NanoViricides files for Rare Pediatric Disease Designation for Measles Drug [Yahoo! Finance]
NanoViricides, Inc. (NNVC)
NASDAQ:AMEX Investor Relations:
nanoviricides.com/investorinfo.html
Company Research
Source: Yahoo! Finance
FDA's Office of Orphan Products Development for NV-387 as a treatment for measles. The RPDD application is expected to be combined with the company's previously submitted Orphan Drug Designation application for NV-387, filed in February 2026, as part of a broader regulatory strategy to advance the drug candidate. If granted, the designation would make NanoViricides eligible for a Priority Review Voucher upon approval of NV-387. PRVs are tradable assets that have recently commanded values of approximately $160 million, reflecting their ability to accelerate regulatory review timelines for other drugs. Diwan emphasized the potential impact of NV-387, stating the therapy could become an important tool in addressing the resurgence of measles in the United States and globally. He added that treatment with NV-387 may support rapid recovery while helping to reduce complications, including the rare but serious post-measles “immune amnesia” effect. Currently, there are no approved antivi
Show less
Read more
Impact Snapshot
Event Time:
NNVC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NNVC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NNVC alerts
High impacting NanoViricides, Inc. news events
Weekly update
A roundup of the hottest topics
NNVC
News
- InvestorNewsBreaks – NanoViricides (NYSE American: NNVC) to Initiate Phase II MPox Trial in DRC [TheStreet.com]TheStreet.com
- NanoViricides completes manufacturing of NV-387 oral drug ahead of Phase II mpox trial [Yahoo! Finance]Yahoo! Finance
- NanoViricides CEO discusses progress of broad-spectrum antiviral candidate NV-387 - ICYMI [Yahoo! Finance]Yahoo! Finance
- NanoViricides: Fiscal Q2 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- NanoViricides seeks FDA orphan status for MPox drug [Yahoo! Finance]Yahoo! Finance
NNVC
Sec Filings
- 2/25/26 - Form D
- 2/17/26 - Form 10-Q
- NNVC's page on the SEC website